MDT vs NVCR
MDT: Global medical device leader deploying pacemakers, defibrillators, spinal implants, surgical robotics, and diabetes management systems to alleviate pain, restore health, and extend life across 150+ countries. NVCR: Novocure delivers Tumor Treating Fields therapy through wearable medical devices to treat aggressive cancers including glioblastoma, lung cancer, and pancreatic cancer.
Side-by-side fundamentals
| Metric | MDT | NVCR | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $81.89 | $15.57 | |
| Market cap as of 2026-07-23 | $105.1B | $1.8B | |
| P/E as of 2026-07-23 | 21.88 | n/a | |
| PEG as of 2026-07-23 | 2.90 | -6.82 | NVCR lower |
| Net margin as of 2026-07-23 | +13.2% | -25.7% | MDT higher |
| Gross margin as of 2026-07-23 | +65.3% | +75.4% | NVCR higher |
| Operating margin as of 2026-07-23 | +17.8% | -27.0% | MDT higher |
| ROE as of 2026-07-23 | +9.8% | -39.4% | MDT higher |
| ROA as of 2026-07-23 | +5.2% | -13.5% | MDT higher |
| Debt / equity as of 2026-07-23 | 0.57 | 0.59 | MDT lower |
| Revenue growth (YoY) as of 2026-07-23 | +8.4% | +8.5% | NVCR higher |
| Revenue CAGR (3y) SEC XBRL | +5.2% | +6.8% | NVCR higher |
| Dividend yield as of 2026-07-23 | +3.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 0.57 | 1.03 | |
| 1-year return as of 2026-07-22 close | -10.6% | -4.5% | NVCR higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.